{"id":"doi:10.1001/jamanetworkopen.2020.0423","kind":"article","title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","authors":["Haslam A","Gill J","Prasad V"],"author_count":3,"year":2020,"published":"2020-03-02","venue":"JAMA network open","cited_by":248,"doi":"10.1001/jamanetworkopen.2020.0423","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jamanetworkopen.2020.0423","archive_url":"https://space-kitty.com/papers/doi:10.1001/jamanetworkopen.2020.0423","updated":null,"pmid":"32150268","pmcid":"PMC7063495","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC7063495/pdf","abstract":null,"abstract_license":null,"license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Metadata: Europe PMC (EMBL-EBI).","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}